By Gabriel Paijo 
A comprehensive study conducted by Brazilian scientists has identified a critical molecular mechanism that allows pancreatic cancer to infiltrate the nervous system during its earliest stages, a discovery that could redefine the approach to treating one of the world’s most lethal malignancies. Published in the prestigious journal Molecular and Cellular Endocrinology, the research highlights the role of a protein known as periostin, which, in conjunction with specialized pancreatic stellate cells, facilitates the aggressive spread of adenocarcinoma. By mapping the interaction between cancer cells and the surrounding tissue, the team from the Center for Research on Inflammatory Diseases (CRID) has opened new doors for precision medicine and targeted therapies designed to halt metastasis before it becomes irreversible.
The Biological Mechanics of Early-Stage Invasion
Pancreatic ductal adenocarcinoma (PDAC), which accounts for approximately 90% of all pancreatic cancer cases, is notorious for its ability to spread long before clinical symptoms appear. The Brazilian study focused on a phenomenon known as perineural invasion (PNI), a process where cancer cells migrate toward and eventually wrap around nearby nerves. Unlike other forms of metastasis that rely primarily on the bloodstream or the lymphatic system, PNI provides a direct "highway" for cancer cells to exit the primary tumor site and move into the central nervous system and other organs.
The researchers found that this process is not driven by the cancer cells alone but is the result of a complex "reprogramming" of the tumor microenvironment. Central to this process are pancreatic stellate cells (PSCs). In a healthy pancreas, these cells remain in a quiescent state, helping to maintain the organ’s structural integrity. However, when a tumor is present, these cells are "activated" and begin to produce high levels of periostin. This protein acts as a remodeling agent for the extracellular matrix—the scaffolding that holds cells together. By softening and restructuring this matrix, periostin creates a path of least resistance, allowing malignant cells to break through healthy tissue and invade nerve bundles.
A Global Health Crisis: Understanding the Aggressive Nature of PDAC
The urgency of this research is underscored by the devastating statistics associated with pancreatic cancer. Globally, the disease remains one of the few major cancers where the mortality rate closely mirrors the incidence rate. According to recent data, there are approximately 510,000 new cases diagnosed annually worldwide, with a nearly identical number of deaths reported in the same period. This suggests that for the vast majority of patients, current diagnostic and therapeutic tools are insufficient.
In Brazil, the National Cancer Institute (INCA) estimates approximately 11,000 new cases and 13,000 deaths each year, reflecting the high number of late-stage diagnoses. Pedro Luiz Serrano Uson Junior, an oncologist and co-author of the study, notes that the five-year survival rate remains stubbornly low, at roughly 10%. "The aggressive nature of this cancer is tied to its ability to evade the immune system and its physical resistance to drugs," Uson explained. "Perineural invasion is a primary marker of this aggressiveness. Once the cancer reaches the nerves, the prognosis drops significantly because the nerves act as conduits to the rest of the body."
Mapping the Tumor Microenvironment Through Spatial Transcriptomics
The study’s breakthroughs were made possible through the use of cutting-edge technology known as spatial transcriptomics. Led by researcher Carlos Alberto de Carvalho Fraga and principal investigator Helder Nakaya—a senior researcher at Einstein Israelite Hospital and professor at the University of São Paulo—the team analyzed 24 individual pancreatic cancer samples.
Traditional genetic sequencing often involves grinding up a tissue sample to see which genes are active, which loses the context of where those cells were located. Spatial transcriptomics, however, allows scientists to see exactly which genes are "turned on" in specific locations within the tumor. "We were able to integrate data from dozens of samples with extremely powerful resolution," Nakaya stated. This high-resolution mapping revealed that the stroma—the connective tissue surrounding the tumor—was not just a passive bystander but an active participant in the cancer’s progression.
The data showed a clear correlation: in areas where periostin levels were highest, the surrounding tissue showed the most significant signs of disruption, and cancer cells were more likely to be found in close proximity to nerve fibers. This spatial evidence confirmed that periostin is a primary driver of the physical changes required for nerve invasion.
The Desmoplastic Reaction: A Physical Barrier to Treatment
One of the most significant challenges in treating pancreatic cancer is the "desmoplastic reaction," a process the study further elucidates. As the tumor and stellate cells produce periostin and other proteins, they create a dense, fibrous, and "scar-like" environment around the malignancy. This hardened tissue creates high interstitial pressure within the tumor, which effectively acts as a physical shield.
This shield prevents chemotherapy and immunotherapy drugs from reaching the cancer cells in effective concentrations. While the drugs may circulate in the bloodstream, the dense stroma acts as a wall, protecting the tumor from the very treatments designed to destroy it. By identifying periostin as a key architect of this wall, the researchers believe they have found a potential "Achilles’ heel." If the production of periostin can be inhibited, it may be possible to prevent the formation of this dense barrier, thereby making the tumor more susceptible to standard treatments.
Chronology of Discovery and the Path to Precision Medicine
The discovery of periostin’s role in pancreatic cancer is the result of years of evolving research into the tumor microenvironment.
- Early 2000s: Research began to shift from looking solely at cancer cells to investigating the "stroma" or supporting tissues.
- 2010-2015: Studies in breast and colon cancer identified periostin as a factor in bone metastasis, sparking interest in its role in other aggressive cancers.
- 2020-2023: The Brazilian team at CRID utilized public genomic databases and advanced computational biology to re-examine existing data through the lens of spatial organization.
- 2024: The publication in Molecular and Cellular Endocrinology provides the first definitive link between periostin, stellate cells, and early-stage nerve invasion in the pancreas.
This timeline reflects a broader shift in oncology toward precision medicine—treating the specific molecular characteristics of a patient’s tumor rather than just the organ of origin. "In the future, we won’t just say a patient has pancreatic cancer," Uson noted. "We will identify that they have a periostin-heavy tumor environment and treat them with specific antibodies designed to break down that defense."
Implications for Future Therapies and Clinical Trials
The findings have immediate implications for the development of new drugs. Currently, clinical trials in other areas of oncology are testing monoclonal antibodies designed to block periostin activity. The Brazilian researchers suggest that these efforts should now be expanded to include pancreatic cancer patients, particularly those in the early stages of the disease.
Reducing the activity of periostin or selectively "silencing" the activated stellate cells could serve two purposes:
- Preventing Spread: By keeping the extracellular matrix intact, the cancer cells remain localized, making surgical removal more effective.
- Enhancing Drug Delivery: By preventing the desmoplastic reaction, chemotherapy can penetrate the tumor more deeply, potentially increasing survival rates.
Furthermore, because perineural invasion is also a feature of other difficult-to-treat cancers, such as certain types of prostate, head and neck, and colorectal cancers, the insights gained from this study could have a "multiplier effect" across the field of oncology.
Institutional Collaboration and Data Science
The success of the study also highlights the growing importance of international and inter-institutional collaboration. The research involved the Center for Research on Inflammatory Diseases (CRID), the University of São Paulo, and Einstein Israelite Hospital, and utilized vast amounts of data from public repositories.
"We were able to ask and answer new questions that the original authors of public datasets hadn’t considered," Nakaya said, emphasizing that the "democratization of data" allows researchers in countries like Brazil to lead world-class scientific breakthroughs. The use of artificial intelligence and machine learning to process these massive datasets was essential in identifying the specific signaling pathways between stellate cells and the nervous system.
Conclusion: A New Frontier in Pancreatic Cancer Research
While pancreatic cancer remains a formidable foe, the identification of the periostin-nerve invasion axis provides a concrete target for intervention. The study moves the scientific community closer to a reality where "early spread" is no longer an inevitable death sentence. By focusing on the structural "reprogramming" of healthy tissue, researchers are moving beyond the cancer cell itself to understand the entire ecosystem of the disease.
As the medical community moves toward the next phase of clinical validation, the focus will remain on developing therapies that can act before the "highway" of nerve invasion is fully paved. For the thousands of patients diagnosed each year, these molecular insights represent a significant step toward turning a high-mortality disease into a manageable, and eventually curable, condition. The work of the Brazilian team stands as a testament to the power of spatial biology and the continuing evolution of precision oncology.
